- Home
- Companies
- Nanolive SA
- Software
- Nanolive - EVE Analytics Software for ...
Nanolive - EVE Analytics Software for Live Cell Imaging and Analysis
EVE Analytics is an advanced image analysis package developed by Nanolive designed for live cell imaging and analysis. It operates in conjunction with Nanolive's 3D Cell Explorer series, including the 96focus and Explorer-fluo, offering a significant advancement in quantitative cell imaging. EVE Analytics provides a user-friendly interface for segmenting and analyzing high-content, biologically relevant data, delivering metrics such as dry mass, cell count, and cell circularity in parallel. This package is particularly useful for long-term experiments as it manages significant changes in cell confluency without quality loss. EVE Analytics captures continuous, multiplexed data, allowing for detailed, simultaneous analyses of cell morphology and population dynamics. The label-free technology revolves around high-resolution imaging over extended periods, overcoming the complexities of manual image analysis through computer-aided processing, thus facilitating the understanding and visualization of intricate biological processes.
EVE Analytics – Continuous, multiplexed live cell data, multi-parametric readout
Nanolive’s 3D Cell Explorer 96focus and 3D Cell Explorer-fluo together with its quantification software EVE Analytics, represents a significant breakthrough in the field of quantitative live cell imaging and analysis.
EVE Analytics’ user-friendly interface offers a segmentation and analysis solution specific to Nanolive’s content rich data which can deliver meaningful metrics with the highest biological relevance.
Works over long-term experiments where cell confluency changes significantly with no reduction in quality and automatically calculates and delivers numerous live cell metrics in parallel such as dry mass, cell count, cell confluency, cell circularity, cell perimeter, cell area, etc.
Cell behavior is a more accurate representation of disease than a single molecular target, so the activity of therapeutic candidates will likely be more predictable in the clinic.
Quantifying changes in cell behavior unveils new targets in diseases for which there are currently no known targets.
